What is the clinical evidence from this study?

Study design: Other. Population: Doxorubicin mitochondrial cardiotoxicity. Intervention: Doxorubicin vs. Baseline conditions (no doxorubicin). Primary outcome: Mitochondrial dysfunction (ATP concentration, membrane potential, ROS production, mtDNA content).

November 21, 2016PLoS Computational BiologyOpen Access

A Biophysical Systems Approach to Identifying the Pathways of Acute and Chronic Doxorubicin Mitochondrial Cardiotoxicity

View Full Paper

Ask AI

Bookmark

Key result

Simulations predict that electron transport chain inhibition drives acute doxorubicin toxicity at supratherapeutic doses, while direct mitochondrial DNA damage causes chronic cardiotoxicity.

Population

In silico mathematical model of mitochondria including the citric acid cycle, electron transport chain, ROS…

Comparison

Simulated doxorubicin exposure with or without… vs Simulated baseline conditions or doxorubicin…

Design

Preclinical

Authors

BOBernardo Lino de OliveiraUniversity of Lisbon SNSteven NiedererElectrophysiology

Discussion

Member takes

Implication

Highlights need for mechanism-specific cardioprotection; hypothesis-generating from simulations and requires clinical validation.

Structured PICO

Population

In silico mathematical model of mitochondria including the citric acid cycle, electron transport chain, ROS production and scavenging systems, and mtDNA damage and repair

Intervention

Simulated doxorubicin exposure (acute constant concentrations, dynamic pharmacokinetic dosing, and chronic weekly doses up to 30μM) with or without simulated iron chelation therapy

Comparator

Simulated baseline conditions (no doxorubicin) or doxorubicin without iron chelation

Outcome

Mitochondrial dysfunction (measured by ATP concentration, membrane potential, ROS concentrations, O2 consumption, and mtDNA content)surrogate

This computational model identifies direct mitochondrial DNA damage as the primary driver of chronic doxorubicin cardiotoxicity, providing a mechanistic basis for the partial cardioprotection observed with iron chelators.

Limitations

Simplified model of mtDNA repair activity lumped into a single enzymatic term due to sparsity of experimental data.
Expression of mtDNA encoded proteins was considered proportional to mtDNA content, ignoring potential delays.
Model does not take into account oxidative damage to other structures or proteins, such as lipids or pathways involving calcium dysregulation.
Simplified model of mtDNA repair systems lumped into a single enzymatic term
Expression of mtDNA encoded proteins considered proportional to mtDNA content without delays
Oxidative damage to other structures or proteins (e.g., lipids, calcium dysregulation, mitochondrial permeability transition) not taken into account

Cite This Study

Oliveira et al. (2016) studied Doxorubicin mitochondrial cardiotoxicity. Doxorubicin vs. Baseline conditions (no doxorubicin) was evaluated on Mitochondrial dysfunction (ATP concentration, membrane potential, ROS production, mtDNA content). Simulations predict that electron transport chain inhibition drives acute doxorubicin toxicity at supratherapeutic doses, while direct mitochondrial DNA damage causes chronic cardiotoxicity.

synapsesocial.com/papers/6a95a9d15024d1c8fdcefb98 https://doi.org/10.1371/journal.pcbi.1005214

View Full Paper

Ask AI

Bookmark

A Biophysical Systems Approach to Identifying the Pathways of Acute and Chronic Doxorubicin Mitochondrial Cardiotoxicity

Discussion

Member takes

Implication

Structured PICO

Limitations

Cite This Study

A Biophysical Systems Approach to Identifying the Pathways of Acute and Chronic Doxorubicin Mitochondrial Cardiotoxicity

Discussion

Member takes

Implication

Structured PICO

Limitations

Cite This Study

Also Consider

Also Consider